Jaguar Health, Inc. (Jaguar Animal Health, Inc.) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 30, 2017, reports that Jaguar Animal Health, Inc. (the "Company") entered into an Agreement and Plan of Merger on March 31, 2017, with Napo Pharmaceuticals, Inc. ("Napo"). The transaction involves the acquisition of Napo, a pharmaceutical company, through a merger with a wholly-owned subsidiary of Jaguar. The filing also announces the resignation of the Company's Chief Scientific Officer and the settlement of outstanding Napo debt.
Key Financial Metrics and Transaction Structure
The filing details a complex capital restructuring rather than standard operating financial results. Key financial terms include:
- Debt Settlement: Napo agreed to a cash payment of no less than $8 million to Nantucket Investments Limited ("Nantucket") to reduce outstanding litigation financing obligations.
- Equity Issuance to Creditors: Existing Napo creditors will receive approximately 43,102,595 shares of Jaguar non-voting common stock and 2,005,245 shares of voting common stock in full satisfaction of indebtedness.
- Contingent Consideration: Napo shareholders will receive contingent rights to up to approximately 21.5% of Jaguar's fully diluted shares, subject to the resale of specific shares ("Tranche A Shares") to Nantucket achieving specified cash returns ("Hurdle Amounts").
- New Investment: An existing Napo stockholder will invest $3 million in new funds, receiving approximately 3,243,243 shares of Jaguar common stock.
- Post-Closing Liquidity and Debt: At closing, Napo is expected to have no more than $11.3 million in secured/unsecured debt, $6.2 million in trade payables, and cash of no less than $500,000.
Material Changes and Dilution
The most significant material change is the anticipated dilution of existing Jaguar shareholders. Following the merger, pre-merger Jaguar equity holders are expected to own approximately 25% of the total fully diluted shares, representing a dilution of approximately 75%. Additionally, the Company will change its name to "Jaguar Health, Inc." and authorize a new class of non-voting common stock.
Guidance, Risks, and Contingencies
Conditions Precedent: The merger is subject to stockholder approval from both Jaguar and Napo, as well as other customary closing conditions. The transaction must close by July 31, 2017, or Jaguar may be required to issue 2,000,000 restricted shares to Napo as a termination fee.
Restrictions: Under the Investor Rights Agreement with Nantucket, Jaguar cannot pay dividends or redeem shares without Nantucket's prior written consent, except in limited circumstances.
Management Changes: Roger Waltzman resigned as Chief Scientific Officer, effective April 3, 2017. The Board of Directors and executive management are expected to remain otherwise unchanged.
Forward-Looking Statements: The filing contains predictions regarding the benefits of the acquisition and future financial results, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the exact terms of the "Hurdle Amounts" and vesting conditions for the contingent shares issued to Napo shareholders.
- Confirm the total number of authorized shares and the specific dilution impact on current holdings post-merger.
- Review the definitive Joint Proxy Statement/Prospectus (Form S-4) for detailed risk factors and financial projections.
- Assess the impact of the dividend and share redemption restrictions imposed by Nantucket Investments Limited.
- Monitor the status of stockholder approvals required to consummate the transaction by the July 31, 2017 deadline.